Dossier assessment
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V
Drug assessment at a glance
-
Drug assessment at a glance
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
07-05-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-145
- Commission
- Commission awarded on 17.11.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-145_en
Connected Projects
-
Dossier assessment
Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Addendum
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Addendum to Project A25-145
Status: Commission completed